Online citations, reference lists, and bibliographies.
← Back to Search

Randomized Phase II Trial Of The Efficacy And Safety Of Trastuzumab Combined With Docetaxel In Patients With Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer Administered As First-line Treatment: The M77001 Study Group.

M. Marty, F. Cognetti, D. Maraninchi, R. Snyder, L. Mauriac, M. Tubiana-Hulin, S. Chan, D. Grimes, A. Antón, A. Lluch, J. Kennedy, K. O'Byrne, P. Conte, M. Green, C. Ward, K. Mayne, Jean-Marc Extra
Published 2005 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
PURPOSE This randomized, multicenter trial compared first-line trastuzumab plus docetaxel versus docetaxel alone in patients with human epidermal growth factor receptor 2 (HER2) -positive metastatic breast cancer (MBC). PATIENTS AND METHODS Patients were randomly assigned to six cycles of docetaxel 100 mg/m2 every 3 weeks, with or without trastuzumab 4 mg/kg loading dose followed by 2 mg/kg weekly until disease progression. RESULTS A total of 186 patients received at least one dose of the study drug. Trastuzumab plus docetaxel was significantly superior to docetaxel alone in terms of overall response rate (61% v 34%; P = .0002), overall survival (median, 31.2 v 22.7 months; P = .0325), time to disease progression (median, 11.7 v 6.1 months; P = .0001), time to treatment failure (median, 9.8 v 5.3 months; P = .0001), and duration of response (median, 11.7 v 5.7 months; P = .009). There was little difference in the number and severity of adverse events between the arms. Grade 3 to 4 neutropenia was seen more commonly with the combination (32%) than with docetaxel alone (22%), and there was a slightly higher incidence of febrile neutropenia in the combination arm (23% v 17%). One patient in the combination arm experienced symptomatic heart failure (1%). Another patient experienced symptomatic heart failure 5 months after discontinuation of trastuzumab because of disease progression, while being treated with an investigational anthracycline for 4 months. CONCLUSION Trastuzumab combined with docetaxel is superior to docetaxel alone as first-line treatment of patients with HER2-positive MBC in terms of overall survival, response rate, response duration, time to progression, and time to treatment failure, with little additional toxicity.
This paper references
10.1200/JCO.20.3.719
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.
C. Vogel (2002)
10.1200/JCO.1999.17.9.2639
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.
M. Cobleigh (1999)
10.1016/S1359-6349(04)90861-0
Multicenter phase II trial of three-weekly docetaxel and weekly trastuzumab in HER-2-overexpressing metastatic breast cancer patients: Japan East cancer center breast cancer consortium (JECBC 01 trial)
T. Tabei (2004)
10.1126/SCIENCE.3798106
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
D. Slamon (1987)
10.1056/NEJM200103153441101
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D. Slamon (2001)
10.1016/S1359-6349(04)90883-X
Weekly docetaxel and trastuzumab for her-2-overexpressing metastatic breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study
S. Takao (2004)
10.1159/000055403
Retrospective Analysis of the Safety of Herceptin® Immunotherapy in Metastatic Breast Cancer
N. Cook-Bruns (2001)
10.1159/000055397
Herceptin® Alone or in Combination with Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Pivotal Trials
J. Baselga (2001)
10.3816/CBC.2004.N.005
Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer.
Joshua P Raff (2004)
10.1200/JCO.2002.07.058
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.
F. Esteva (2002)
10.1200/JCO.2001.19.10.2722
Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.
H. Burstein (2001)
10.1016/0304-419X(94)90012-4
The biology of erbB-2/neu/HER-2 and its role in cancer.
N. E. Hynes (1994)
Weekly intravenous recombinant humanized anti-P185HER2 monoclonal antibody (herceptin) plus docetaxel in patients with metastatic breast cancer: a pilot study.
H. Meden (2001)
10.1200/JCO.2004.10.046
Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial.
K. L. Tedesco (2004)
10.1016/S1359-6349(03)90496-4
464 Efficacy and toxicity of docetaxel or cisplatin chemotherapy in combination with trastuzumab in the treatment of patients with chemotherapy pre-treated HER-2/neu overexpressed metastatic breast cancer
B. Bauer-Kosińska (2003)
10.1097/01.COC.0000017087.19671.05
Safety and Activity of Docetaxel and Trastuzumab in HER2 Overexpressing Metastatic Breast Cancer: A Pilot Phase II Study
F. Montemurro (2003)
10.1016/S1359-6349(04)90865-8
Results of a phase II study of liposomal doxorubicin (Myocet®) in combination with weekly paclitaxel and trastuzumab (Herceptin®) In patients with HER2-positive locally advanced or metastatic breast cancer (LA/MBC)
J. Baselga (2004)
Taxanes in the treatment of advanced breast cancer
L. Krasińska (2003)
10.1093/JNCI/DJH131
Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.
M. Pegram (2004)
10.1634/THEONCOLOGIST.7-5-410
Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer.
M. Jahanzeb (2002)
10.1200/JCO.1999.17.8.2341
Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.
S. Chan (1999)
10.1126/SCIENCE.2470152
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.
D. Slamon (1989)
10.1200/JCO.2001.19.10.2587
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.
A. Seidman (2001)
10.1200/JCO.2004.22.14_SUPPL.520
Significantly higher pathological complete remission (PCR) rate following neoadjuvant therapy with trastuzumab (H), paclitaxel (P), and anthracycline-containing chemotherapy (CT): Initial results of a randomized trial in operable breast cancer (BC) with HER/2 positive disease.
A. Buzdar (2004)
10.1023/A:1020587504186
Breast Cancer in Women with Human Immunodeficiency Virus Infection: Implications for Diagnosis and Therapy
B. El-Rayes (2004)
10.1093/ANNONC/MDF076
Fecal occult blood test for colorectal cancer screening.
H. Strul (2002)



This paper is referenced by
10.2147/IJN.S179290
From 3D spheroids to tumor bearing mice: efficacy and distribution studies of trastuzumab-docetaxel immunoliposome in breast cancer
A. Rodallec (2018)
10.5631/JIBIRINSUPPL.152.90
A Case of Salivary Duct Carcinoma in the Submandibular Gland Treated Long-term with a Combination of Trastuzumab and Docetaxel
Saki Yabuuchi (2017)
10.1634/theoncologist.2014-0033
Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA.
S. Swain (2014)
10.1586/14737167.2014.868314
Benefits of investment into modern medicines in Central–Eastern European countries
A. Inotai (2014)
10.1016/s1470-2045(20)30112-1
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
S. Tolaney (2020)
10.1007/s10549-008-9910-y
Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunity
A. Coveler (2008)
HER2 and TP53 in human breast cancer : Studies of methods and prognostic value
J. Bergqvist (2006)
10.1053/J.SEMINONCOL.2006.03.024
Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
H. Lane (2006)
10.1016/J.BREAST.2007.07.024
How to treat male breast cancer.
Czene Kamila (2007)
10.1200/JCO.2007.10.9777
American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects.
J. Carver (2007)
Search for the Holy Grail: evolving targeted therapies in breast cancer
F. Boyle (2008)
10.1016/S1359-6349(08)70283-0
Capecitabine and docetaxel in the treatment of metastatic breast cancer: combination, sequence or single agent?
D. Miles (2008)
10.1080/20742835.2009.11441138
HER-2 positive breast cancer and trastuzumab: lessons learnt by heart
K. Outhoff (2009)
10.1016/S1470-2045(09)70230-X
Management of HER2-positive breast cancer in Asia: consensus statement from the Asian Oncology Summit 2009.
N. S. Wong (2009)
THESE POUR LE DOCTORAT EN MEDECINE
Sophie Gouérant (2012)
10.1007/978-2-8178-0245-9_35
Anti-HER-2 et hormonothérapies dans la prise en charge des cancers du sein: Indications
J. R. Guastalla (2012)
10.1007/s12282-011-0277-2
Can patients with metastatic breast cancer be cured after introduction of newer and more effective agents?
S. Ohno (2011)
10.1016/S0305-7372(05)80002-7
How to maximize the efficacy of taxanes in breast cancer.
M. Tubiana-Hulin (2005)
10.1186/bcr1341
Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis
J. Reis-Filho (2005)
10.1080/02841860500341181
The burden of scientific progress: Growing inequalities in the delivery of cancer care
M. Mano (2006)
10.1093/ANNONC/MDM417
Patients with advanced stage breast carcinoma immunoreactive to biotinylated Herceptin are most likely to benefit from trastuzumab-based therapy: an hypothesis-generating study.
A. Sapino (2007)
10.1093/annonc/mdr474
Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancer.
S. Gori (2012)
10.1093/ANNONC/MDM059
Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcome.
J. Bergqvist (2007)
Metastatic breast cancer : prolongation of survival in routine care is restricted to hormone-receptor-and Her 2-positive tumors
R. Weide (2014)
Difference in physiological parameters following an exercise intervention in breast cancer survivors on a single chemotherapy drug versus combination chemotherapy drugs
Micah John Foster (2010)
Efficacy and Safety of Trastuzumab Added to Standard Treatments for HER 2-positive Metastatic Breast Cancer Patients
Zhen-Li Zhu (2014)
A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER 2 expression : changing the natural history of HER 2-positive disease
P. Papaldo (2006)
Development and characterization of models of resistance to T-DM1
Juliette Sauveur (2016)
10.1159/000258492
Which Patients with Estrogen Receptor-Positive Early Breast Cancer Should Be Treated with Adjuvant Chemotherapy?
Vincenzo Emanuele Chiuri (2009)
10.1586/14737140.8.12.1883
Jumping higher: is it still possible? The ALTTO trial challenge
Gianluca Tomasello (2008)
10.1097/CAD.0000000000000287
Challenges in the implementation of trastuzumab biosimilars: an expert panel’s recommendations
X. Pivot (2015)
Immunity & Ageing the Management of Cancer in the Elderly: Targeted Therapies in Oncology Introduction: the Ageing and Cancer Interface
Biagio Agostara ()
See more
Semantic Scholar Logo Some data provided by SemanticScholar